Demethylation demystification

Lauren Suarez, Steven D. Gore

Research output: Contribution to journalArticle

Abstract

The ability of theDNAmethyltransferase inhibitors (DNMTi) to induce terminal differentiation in fibroblasts was first noted by Taylor and Jones in 19791; Silverman and Holland reported hematologic improvement in patients with myelodysplastic syndrome (MDS) in 1993.2 That azacitidine improves survival in patients with high-riskMDSand acute myeloid leukemia withMDSfeatures compared with a combined comparator group of supportive care, low-dose cytarabine, and intensive cytarabine plus anthracycline, while inducing trilineage normalization in approximately 15% of patients3 makes the development of more potent, more specific drugs that behave like azacitidine imperative. The question is, how do the azanucleosides behave?.

Original languageEnglish (US)
Pages (from-to)1488-1489
Number of pages2
JournalBlood
Volume121
Issue number9
DOIs
StatePublished - Feb 28 2013

Fingerprint

Azacitidine
Cytarabine
Anthracyclines
Myelodysplastic Syndromes
Fibroblasts
Acute Myeloid Leukemia
Netherlands
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Suarez, L., & Gore, S. D. (2013). Demethylation demystification. Blood, 121(9), 1488-1489. https://doi.org/10.1182/blood-2013-02-483735

Demethylation demystification. / Suarez, Lauren; Gore, Steven D.

In: Blood, Vol. 121, No. 9, 28.02.2013, p. 1488-1489.

Research output: Contribution to journalArticle

Suarez, L & Gore, SD 2013, 'Demethylation demystification', Blood, vol. 121, no. 9, pp. 1488-1489. https://doi.org/10.1182/blood-2013-02-483735
Suarez L, Gore SD. Demethylation demystification. Blood. 2013 Feb 28;121(9):1488-1489. https://doi.org/10.1182/blood-2013-02-483735
Suarez, Lauren ; Gore, Steven D. / Demethylation demystification. In: Blood. 2013 ; Vol. 121, No. 9. pp. 1488-1489.
@article{a462aa1add1d4997861ea5565d58c603,
title = "Demethylation demystification",
abstract = "The ability of theDNAmethyltransferase inhibitors (DNMTi) to induce terminal differentiation in fibroblasts was first noted by Taylor and Jones in 19791; Silverman and Holland reported hematologic improvement in patients with myelodysplastic syndrome (MDS) in 1993.2 That azacitidine improves survival in patients with high-riskMDSand acute myeloid leukemia withMDSfeatures compared with a combined comparator group of supportive care, low-dose cytarabine, and intensive cytarabine plus anthracycline, while inducing trilineage normalization in approximately 15{\%} of patients3 makes the development of more potent, more specific drugs that behave like azacitidine imperative. The question is, how do the azanucleosides behave?.",
author = "Lauren Suarez and Gore, {Steven D.}",
year = "2013",
month = "2",
day = "28",
doi = "10.1182/blood-2013-02-483735",
language = "English (US)",
volume = "121",
pages = "1488--1489",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Demethylation demystification

AU - Suarez, Lauren

AU - Gore, Steven D.

PY - 2013/2/28

Y1 - 2013/2/28

N2 - The ability of theDNAmethyltransferase inhibitors (DNMTi) to induce terminal differentiation in fibroblasts was first noted by Taylor and Jones in 19791; Silverman and Holland reported hematologic improvement in patients with myelodysplastic syndrome (MDS) in 1993.2 That azacitidine improves survival in patients with high-riskMDSand acute myeloid leukemia withMDSfeatures compared with a combined comparator group of supportive care, low-dose cytarabine, and intensive cytarabine plus anthracycline, while inducing trilineage normalization in approximately 15% of patients3 makes the development of more potent, more specific drugs that behave like azacitidine imperative. The question is, how do the azanucleosides behave?.

AB - The ability of theDNAmethyltransferase inhibitors (DNMTi) to induce terminal differentiation in fibroblasts was first noted by Taylor and Jones in 19791; Silverman and Holland reported hematologic improvement in patients with myelodysplastic syndrome (MDS) in 1993.2 That azacitidine improves survival in patients with high-riskMDSand acute myeloid leukemia withMDSfeatures compared with a combined comparator group of supportive care, low-dose cytarabine, and intensive cytarabine plus anthracycline, while inducing trilineage normalization in approximately 15% of patients3 makes the development of more potent, more specific drugs that behave like azacitidine imperative. The question is, how do the azanucleosides behave?.

UR - http://www.scopus.com/inward/record.url?scp=84876444975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876444975&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-02-483735

DO - 10.1182/blood-2013-02-483735

M3 - Article

C2 - 23449614

AN - SCOPUS:84876444975

VL - 121

SP - 1488

EP - 1489

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -